HLA-G and neoplasm: In conclusion, we have developed a dual‐targeting mRNA‐engineered Nb‐CAR.BiTE‐Vδ2 γδT therapy is capable of overcoming the HLA‐G/PD‐L1 checkpoint dilemma and even destroying antigen‐inadequate tumor cells, which leads to potent anti‐tumor activity with no apparent toxicity.